Landscape analysis and oncologic outcomes in advanced urothelial carcinoma by NECTIN4 RNA expression

Authors:

Tyler Stewart, Sarah Fenton, Shayan Nazari, Andrew Elliott, Rohan Garje, Amirali Salmasi, Aditya Bagrodia, Chadi Nabhan, David VanderWeele, Rana McKay

Background:

  • Advanced urothelial carcinoma (UC) is a devastating disease, however recent advances with antibody drug conjugates (ADCs), including enfortumab vedotin (EV), have improved outcomes significantly.1,2
  • Currently no biomarkers are clinically available to predict response to therapy EV.
  • We hypothesized that benefit from EV may correlate with RNA expression of NECTIN4, the gene encoding the relevant cell surface antigen for EV.
  • Therefore, we performed a landscape analysis of NECTIN4 in advanced UC and correlated expression with oncologic outcomes.
Download Publication